Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Eli Lilly and Company
Femme et Homme Max 99 ans
Eli Lilly and Company Ltd
MAJ Il y a 4 ans
The DURABLE Trial: Assessing the DURAbility of Basal vs. Lispro Mix 25 Insulin Efficacy The Durability of Twice-Daily Insulin Lispro Low Mixture Compared to Once-Daily Insulin Glargine when added to Existing Oral Therapy in Patients with Type 2 Diabetes and Inadequate Glycemic Control
Initiation Phase The primary objective of the 6-month initiation phase of this study of patients with type 2 diabetes with inadequate glycemic control is to test the hypothesis that addition of twiced...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Eli Lilly and Company
MAJ Il y a 4 ans
A Study of Abemaciclib plus Trastuzumab with or without Fulvestrant in Participants with HR+, HER2+ Metastatic Breast Cancer. Μια μελέτη του Abemaciclib μαζί με Τραστουζουμάμπη με ή χωρίς Φουλβεστράντη σε Συμμετέχουσες Ασθενείς με HR+, HER2+ Μεταστατικό Καρκίνο του Μαστού
The primary objective of this study is to compare the efficacy of abemaciclib plus trastuzumab plus fulvestrant and abemaciclib plus trastuzumab to standard-of-care single-agent chemotherapy of physic...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company
MAJ Il y a 4 ans
A Phase 3 Study in Moderate to Severe Rheumatoid Arthritis
Determine whether baricitinib monotherapy is noninferior to MTX monotherapy in the treatment of patients with moderate to severe active RA who have had limited or no treatment with MTX and are naive t...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Eli Lilly and Company Limited
MAJ Il y a 4 ans
A Phase 3b,randomized,double-blind,placebo-controlled parallel-design study to evaluate the efficacy and safety of tadalafil coadministered with finasteride for 6 months in men with lower urinary tract symptoms(LUTS) and prostatic enlargement secondary to benign prostatic hyperplasia(BPH)
The primary objective of this study is to test the hypothesis that tadalafil 5 mg once daily co-administered with finasteride is superior to placebo once daily co-administered with finasteride for 12 ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company
MAJ Il y a 4 ans
A one year study to compare insulin therapies in Type I diabetic patients
To demonstrate that glycemic control as measured by HbA1c at 52 weeks for LY2605541 is non-inferior compared with insulin glargine when each is combined with pre-prandial insulin lispro in patients wi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company
MAJ Il y a 4 ans
An investigational study to assess the safety and effectiveness of an investigational drug in people with moderate to severe ulcerative colitis
The primary objective of this study is to test the hypothesis that treatment with LY3074828 is superior to placebo in inducing clinical remission at Week 12 (as defined in Section 10.1.1 of the protoc...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Homme Max 99 ans
Eli Lilly and Company Limited
MAJ Il y a 4 ans
Impact of Tadalafil (LY450190) Once a Day or Tadalafil On Demand Compared to Sildenafil Citrate On Demand on Treatment Discontinuation in Patients with Erectile Dysfunction who are Naïve to PDE5 Inhibitors
The primary objective of this study is to assess the impact of tadalafil once a day (OaD) and tadalafil on demand (PRN) compared with sildenafil citrate PRN, in men with erectile dysfunction (ED) who ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company
MAJ Il y a 4 ans
The effect of treatment interruption on safety and efficacy of exenatide in patients with Type 2 Diabetes
To assess the anti exenatide-antibody response to exenatide re-exposure as measured by anti-exenatide antibodies and incidence of treatment-emergent allergy and hypersensitivity reactions following a...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company
MAJ Il y a 4 ans
Study to assess the effect of AZD3293 in early Alzheimer's Disease
To test the hypothesis that AZD3293, administered orally at doses of 20 and 50 mg daily for 104 weeks, will slow the decline of AD as compared with placebo in patients with early AD dementia as measur...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Eli Lilly and Company
MAJ Il y a 4 ans
A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 versus Placebo in Patients with DSM-IVTR Schizophrenia
The primary objective of this study is to test the hypothesis that at least 1 dose level of LY2140023, given orally to patients with schizophrenia at 80 mg BID or 40 mg BID (twice daily), will demonst...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
15
16
17
18
19
20
21
22
23
24
Suivant